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2007-2008 Influenza Season 
Week 5, ending February 2, 2008 
 (All data are preliminary and may change as more reports are received.) 
 
Synopsis:  During week 5 (January 27 – February 2, 2008), influenza activity continued to increase 
in the United States.   
o One thousand five hundred thirty-eight (23.9%) specimens tested by U.S. World Health 
Organization (WHO) and National Respiratory and Enteric Virus Surveillance System 
(NREVSS) collaborating laboratories were positive for influenza. 
o The proportion of deaths attributed to pneumonia and influenza was above the epidemic 
threshold for the fourth consecutive week. 
o The proportion of outpatient visits for influenza-like illness (ILI) and acute respiratory illness 
(ARI) was above national baseline levels. ILI increased in eight of the nine regions 
compared to week 4, and was above region-specific baselines in all nine regions.  The West 
North Central region reported ARI above its region specific baseline.   
o Thirty-one states reported widespread influenza activity; 17 states reported regional 
influenza activity; and two states and the District of Columbia reported local influenza 
activity. 
National and Regional Summary of Select Surveillance Components 
  Data for current week Data cumulative for the season 
  
Sentinel 
Provider 
ILI* 
DoD and 
VA ARI* 
% pos. 
for flu†
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity‡  
A 
(H1) 
A 
(H3) 
A 
Unsub-
typed 
B Pediatric Deaths 
Nation Elevated Elevated 23.9% 48 of 51  860 745 4200 1119 1 
New 
England Elevated Normal 10.8% 5 of 6 26 4 135 104 0 
Mid-
Atlantic Elevated Normal 14.4% 3 of 3 54 15 236 231 0 
East North 
Central Elevated Normal 58.7% 5 of 5 88 229 63 123 0 
West 
North 
Central Elevated Elevated 19.6% 7 of 7 38 20 397 77 0 
South 
Atlantic Elevated Normal 20.5% 7 of 9 88 204 819 184 0 
East 
South 
Central Elevated Normal 22.1% 4 of 4 8 63 14 6 0 
West South 
Central Elevated Normal 28.1% 4 of 4 42 139 1888 147 1 
Mountain Elevated Normal 17.2% 8 of 8 255 41 348 144 0 
Pacific Elevated Normal 16.9% 5 of 5 261 30 300 103 0 
 
* Elevated means the % of visits for ILI or ARI is at or above the national or region-specific baseline 
† National data are for current week; regional data are for the most recent three weeks. 
‡ Includes all 50 states and the District of Columbia 
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Laboratory Surveillance:  During week 5, WHO and NREVSS laboratories reported 6,430 
specimens tested for influenza viruses, 1,538 (23.9%) of which were positive, including 81 influenza 
A (H1) viruses, 248 influenza A (H3) viruses, 916 influenza A viruses that were not subtyped, and 
293 influenza B viruses.  The District of Columbia and 47 states from all nine surveillance regions 
have reported laboratory-confirmed influenza this season. 
 
Since September 30, 2007, WHO and NREVSS laboratories have tested a total of 82,705 
specimens for influenza viruses and 6,924 (8.4%) were positive. Among the 6,924 influenza 
viruses, 5,805 (83.8%) were influenza A viruses and 1,119 (16.2%) were influenza B viruses.  One 
thousand six hundred five (27.6%) of the 5,805 influenza A viruses have been subtyped: 860 
(53.6%) were influenza A (H1) viruses and 745 (46.4%) were influenza A (H3) viruses. 
 
Although influenza A (H1) viruses have been the predominant subtype overall this season, 
influenza A (H3) viruses have been reported more frequently than A (H1) viruses in the past two 
weeks.  This season influenza A (H3) viruses have been reported more frequently than A (H1) 
viruses in four of the nine surveillance regions (East North Central, East South Central, South 
Atlantic, and West South Central). 
 
U.S. WHO/NREVSS Collaborating Laboratories
National Summary, 2007-08
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Antigenic Characterization:  CDC has antigenically characterized 197 influenza viruses [101 
influenza A (H1N1), 53 influenza A (H3N2), and 43 influenza B viruses] collected by U.S. 
laboratories since September 30, 2007. 
 
Influenza A (H1N1) [101] 
• Ninety-seven (96%) of the 101 viruses were characterized as A/Solomon 
Islands/3/2006, the influenza A (H1N1) component of the 2007-08 influenza vaccine 
for the Northern Hemisphere and the 2008 influenza A (H1N1) component for the 
Southern Hemisphere. 
• Four (4%) of the 101 viruses showed somewhat reduced titers with antisera 
produced against A/Solomon Islands/3/2006. 
Influenza A (H3N2) [53] 
• Six (11%) of the 53 viruses were characterized as A/Wisconsin/67/2005-like, the 
influenza A (H3N2) component of the 2007-08 influenza vaccine for the Northern 
Hemisphere. 
• Fourty-six (87%) of the 53 viruses were characterized as A/Brisbane/10/2007-like.  
A/Brisbane/10/2007 is a recent antigenic variant which evolved from 
A/Wisconsin/67/2005-like.  A/Brisbane/10/2007-like virus is the recommended 
influenza A (H3N2) component for the 2008 Southern Hemisphere vaccine. 
• One (2%) of the 53 viruses showed somewhat reduced titers with antisera produced 
against A/Wisconsin/67/2005 and A/Brisbane/10/2007. 
 
Influenza B (B/Victoria/02/87 and B/Yamagata/16/88 lineages) [43] 
  
Victoria lineage [3] 
• Three (7%) of the 43 influenza B viruses characterized belong to the B/Victoria 
lineage of viruses. 
o Two (67%) of these 3 viruses were characterized as B/Ohio/01/2005-like. The 
recommended influenza B component for the 2007-08 influenza vaccine is a 
B/Malaysia/2506/2004-like virus, belonging to the B/Victoria lineage.  
B/Ohio/01/2005 is a recent B/Malaysia/2506/2004-like reference strain. 
o One (33%) of these 3 viruses showed somewhat reduced titers with antisera 
produced against B/Ohio/01/2005 and B/Malaysia/2506/2004.  
 
Yamagata lineage [40] 
• Forty (93%) of the 43 viruses were identified as belonging to the B/Yamagata lineage 
of viruses. 
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Antiviral Resistance: In the United States, two groups of antiviral drugs have been approved by 
the FDA for use in treating or preventing influenza infections.  These two groups of antiviral drugs 
are: neuraminidase inhibitors (oseltamivir and zanamavir) and adamantanes (amantadine and 
rimantidine). A description of these drugs can be found at: 
http://www.cdc.gov/flu/protect/antiviral/index.htm.  
 
Neuraminidase Inhibitor Antiviral Drugs: Small numbers of influenza viruses resistant to 
the neuraminidase inhibitor oseltamivir have been detected in the United States.  Of the 331 
influenza A and B viruses tested for antiviral resistance so far this season, 15 (4.5%) have 
been found to be resistant to oseltamivir.  Currently all of the resistant viruses are H1N1 
viruses, with 15 (8.1%) of all H1N1 viruses exhibiting a genetic mutation that confers 
oseltamivir resistance.  These resistant viruses have been found sporadically across 4 of the 
9 surveillance regions.  All tested viruses retain their sensitivity to zanamavir.  Additional 
information on antiviral resistance can be found at: 
http://www.cdc.gov/flu/about/qa/antiviralresistance.htm 
 
Adamantane Antiviral Drugs: Resistance to the adamantanes continues to be high.  
Among 189 influenza A viruses tested, 84 (44.4%) are resistant to adamantanes, including 
99% of H3N2 viruses and 8.3% of H1N1 viruses.  The adamantanes are not effective 
against influenza B viruses.   
 
Based on the level of oseltamivir resistance observed in only one influenza subtype, H1N1, 
and persisting high levels of resistance to the adamantanes in both H3N2 and H1N1 
viruses, CDC continues to recommend the use of oseltamivir and zanamavir for the 
treatment or prevention of influenza.  Use of amantadine or rimantadine is not 
recommended.  Guidance on influenza antiviral use can be found at: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5606a1.htm 
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 5, 8.2% of all deaths 
reported through the 122-Cities Mortality Reporting System were reported as due to P&I. This 
percentage is above the epidemic threshold of 7.1% for week 5.  Including week 5, P&I mortality 
has been above threshold for four consecutive weeks. 
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Influenza-Associated Pediatric Mortality: No influenza-associated pediatric deaths were officially 
reported to CDC during week 5 due to technical problems with the reporting system; a total of one 
influenza-associated pediatric death was reported previously for the 2007-08 season.  However, 
unofficial notifications were received for five deaths and these will be included in next week’s report.  
 
Number of Influenza-Associated Pediatric Deaths
by Week of Death:
2005-06 season to present
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Influenza-Associated Pediatric Hospitalizations:  Laboratory-confirmed influenza-associated 
pediatric hospitalizations are monitored in two population-based surveillance networks: the New 
Vaccine Surveillance Network (NVSN) and the Emerging Infections Program (EIP).   
During November 4, 2007-January 26, 2008, the preliminary laboratory-confirmed influenza-
associated hospitalization rate reported by the NVSN for children 0-4 years old was 0.73 per 
10,000.   
NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children 0 - 4 Years, 2007- 08 and Previous 2 Seasons
0
1
2
3
4
5
6
40-41 42-43 44-45 46-47 48-49 50-51 52 -1 2-3 4-5 6-7 8-9 10-11 12-13 14-15 16-17 18-19 20-21
2007-2008 Influenza Season 
2 Week Reporting Period
P
op
ul
at
io
n-
B
as
ed
 R
at
e 
pe
r 
10
,0
00
 C
hi
ld
re
n
2005-2006 2006-2007 2007-2008
 
 
 
 
 
 
 
 
2007-2008 Influenza Season – Week 5, ending February 2, 2008           
 
7
 
During September 30 – January 19, 2008, the preliminary laboratory-confirmed influenza-
associated hospitalization rate reported by the EIP for children 0–17 years old was 0.25 per 10,000.  
For children aged 0-4 years and 5-17 years, the rate was 0.7 per 10,000 and 0.07 per 10,000, 
respectively.
EIP Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children Aged 0-4 and 5-17 yrs, 2007-2008 and 
Previous 2 Seasons
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Outpatient Illness Surveillance:  Nationwide during week 5, 5.1% of outpatient visits reported 
through the U.S. Influenza Sentinel Provider Surveillance Network were due to influenza-like illness 
(ILI), which is above the national baseline of 2.2%.  On a regional level, the percentage of visits for 
ILI increased in all nine regions compared to last week and ranged from 2.7% to 10.4%.  All nine 
regions reported ILI above their region-specific baselines.  
 
Starting in week 5, New York City began reporting ILI data collected electronically from emergency 
departments city-wide, adding approximately 60,000 additional patient visits per week to the U.S. 
Influenza Sentinel Provider Surveillance Network.  Retrospective reports were submitted for all 
earlier weeks this season.  While this change increases the total patient visits per week by 
approximately 15%, it is not expected to influence the national ILI outpatient visit percentage after 
population weighting, but may have a larger impact on the Mid-Atlantic regional ILI percentage. 
 
During week 5, 3.2% of patient visits to Department of Veteran’s Affairs (VA) and Department of 
Defense (DoD) outpatient treatment facilities were for acute respiratory illness (ARI), which was at 
the national baseline of 3.2%.  On a regional level, the percentage of visits for ARI ranged from 
1.4% to 4.0%, and was slightly above the West North Central region-specific baseline.  The 
percentage of visits reported for ARI was above age-specific baselines in the 5-17 year, 18-49 year, 
and 50-64 year age groups.   
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Percentage of Visits for ILI & ARI Reported
by Sentinel Providers and BioSense Outpatient Facilities,
National Summary
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Percentage of Visits for ARI by Age Group Reported by 
DoD/VA Outpatient Clinics - National Summary
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: During 
week 5 the following influenza activity was reported: 
• Widespread activity was reported by 31 states (Alabama, Alaska, Arizona, Arkansas, 
Colorado, Connecticut, Delaware, Georgia, Hawaii, Idaho, Indiana, Iowa, Kansas, Kentucky, 
Louisiana, Maryland, Massachusetts, Mississippi, Nebraska, New Jersey, New Mexico, New 
York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Texas, 
Vermont, and Virginia). 
• Regional activity was reported by 17 states (California, Illinois, Michigan, Minnesota, 
Missouri, Montana, Nevada, New Hampshire, North Dakota, Oregon, Rhode Island, 
Tennessee, Utah, Washington, West Virginia, Wisconsin, and Wyoming). 
• Local activity was reported by the District of Columbia and two states (Florida and Maine). 
 
 
 
 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: February 8, 2008.
  
